Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4526MR)

This product GTTS-WQ4526MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4526MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12375MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ2743MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ8509MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ14177MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ5024MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ8467MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2526MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ6175MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-751871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW